Daihan Pharmaceutical Co.,Ltd. (KOSDAQ: 023910)

Daihan Pharmaceutical Co.,Ltd. Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	68,383	101,501	90,857	83,765	61,398	44,836
Short-Term Investments	3,506	2,858	6,750	12,650	6,202	9,030
Cash & Short-Term Investments	73,889	104,359	97,607	96,415	67,600	53,866
Cash Growth	-28.32%	6.92%	1.24%	42.63%	25.50%	26.37%
Accounts Receivable	30,210	30,857	31,306	29,101	28,947	35,949
Other Receivables	976	85.13	932.21	71.32	130.33	211.21
Receivables	31,186	30,942	32,238	29,172	29,077	36,160
Inventory	26,596	23,588	24,939	20,632	23,733	19,951
Prepaid Expenses	82.19	79.94	74.87	107.4	162.26	97.99
Other Current Assets	707.55	935.43	1,026	1,212	1,111	1,055
Total Current Assets	132,461	159,905	155,886	147,539	121,684	111,130
Property, Plant & Equipment	132,437	125,853	113,236	113,831	113,396	125,820
Long-Term Investments	48,027	8,065	7,394	10,129	16,861	8,437
Other Intangible Assets	397.01	397.01	397.01	397.01	397.51	400.4
Long-Term Accounts Receivable	-	-	0	-	-	-
Long-Term Deferred Tax Assets	-	-	-	398.84	493.64	815.71
Other Long-Term Assets	33	33	67.34	247.34	257.34	248.34
Total Assets	313,354	294,252	276,980	272,542	253,090	246,852
Accounts Payable	17,086	17,227	18,104	15,108	15,497	15,953
Accrued Expenses	577.37	777.66	739.86	674.52	639.34	646.97
Short-Term Debt	-	-	2,500	2,700	3,700	5,000
Current Portion of Long-Term Debt	-	-	-	6,800	4,000	2,000
Current Portion of Leases	-	-	-	16.57	242.41	43.67
Current Income Taxes Payable	4,849	4,466	5,130	5,662	1,124	4,343
Other Current Liabilities	15,837	18,830	16,211	15,158	14,021	14,730
Total Current Liabilities	38,350	41,300	42,686	46,119	39,224	42,717
Long-Term Debt	-	-	4,000	14,000	20,800	24,800
Long-Term Leases	-	-	-	-	16.57	-
Long-Term Deferred Tax Liabilities	686.03	303.87	775.87	-	-	-
Other Long-Term Liabilities	616.93	594.63	565.8	506.37	845.57	980.75
Total Liabilities	45,019	46,278	51,582	69,734	71,166	80,076
Common Stock	3,000	3,000	3,000	3,000	3,000	3,000
Additional Paid-In Capital	175.92	175.92	175.92	175.92	175.92	175.92
Retained Earnings	258,886	238,525	216,086	190,078	169,194	154,045
Treasury Stock	-3,418	-3,418	-3,418	-	-	-
Comprehensive Income & Other	9,691	9,691	9,554	9,554	9,554	9,554
Shareholders' Equity	268,335	247,974	225,398	202,808	181,923	166,775
Total Liabilities & Equity	313,354	294,252	276,980	272,542	253,090	246,852
Total Debt	-	-	6,500	23,517	28,759	31,844
Net Cash (Debt)	73,889	104,359	91,107	72,899	38,841	22,023
Net Cash Growth	-28.32%	14.55%	24.98%	87.68%	76.37%	421.15%
Net Cash Per Share	12566.09	17748.21	15224.38	12148.46	6473.96	3670.11
Filing Date Shares Outstanding	5.88	5.88	5.88	6	6	6
Total Common Shares Outstanding	5.88	5.88	5.88	6	6	6
Working Capital	94,111	118,604	113,200	101,420	82,460	68,414
Book Value Per Share	45635.20	42172.46	38333.01	33801.34	30320.57	27795.88
Tangible Book Value	267,938	247,577	225,001	202,411	181,526	166,375
Tangible Book Value Per Share	45567.68	42104.94	38265.49	33735.17	30254.32	27729.14
Land	59,385	59,380	56,796	55,727	55,727	55,727
Buildings	68,627	61,781	59,354	49,971	49,420	56,180
Machinery	83,584	81,358	78,438	77,615	77,976	73,193
Construction In Progress	17,070	15,484	3,225	8,857	1,995	3,562

Source: S&P Capital IQ. Standard template. Financial Sources.